Wednesday 18 September 2013

Servier in licensing pact with SIMM for the development in China of lucitanib

Servier has signed an agreement with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, (SIMM)  for the development in China of lucitanib, a promising targeted anti-tumor drug with antiangiogenic effects. The drug has demonstrated impressive efficacy in PhI/PhII trials in metastatic breast cancer patients

Monday 16 September 2013

Azaya therapeutics outlicenses rights to liposomal docetaxel (AT1123) to Beijing’s CANbridge Lifescience

CANbridge Life Sciences, a Beijing in-licensing firm, has secured the China rights to a cancer drug from Azaya Therapeutics of San Antonio, TX. The drug, ATI-1123, is a liposomal formulation of docetaxel that has completed a Phase I trial in the US. CANbridge will fund clinical development of ATI-1123 for non-small cell lung cancer in China, Taiwan and Korea, collaborating with Azaya on clinical trial design. - See more at: http://www.chinabiotoday.com/articles/20130912_1#sthash.AcVTng61.dpuf
CANbridge Life Sciences, a Beijing in-licensing firm, has secured the China rights to a cancer drug from Azaya Therapeutics of San Antonio, TX. The drug, ATI-1123, is a liposomal formulation of docetaxel that has completed a Phase I trial in the US. CANbridge will fund clinical development of ATI-1123 for non-small cell lung cancer in China, Taiwan and Korea, collaborating with Azaya on clinical trial design. - See more at: http://www.chinabiotoday.com/articles/20130912_1#sthash.AcVTng61.dpuf
CANbridge Life Sciences, a Beijing in-licensing firm, has secured the China rights to a cancer drug from Azaya Therapeutics of San Antonio, TX. The drug, ATI-1123, is a liposomal formulation of docetaxel that has completed a Phase I trial in the US. CANbridge will fund clinical development of ATI-1123 for non-small cell lung cancer in China, Taiwan and Korea, collaborating with Azaya on clinical trial design. - See more at: http://www.chinabiotoday.com/articles/20130912_1#sthash.AcVTng61.dpuf
CANbridge Life Sciences, a Beijing in-licensing firm, has secured the China rights to a cancer drug from Azaya Therapeutics of San Antonio, TX. The drug, ATI-1123, is a liposomal formulation of docetaxel that has completed a Phase I trial in the US. CANbridge will fund clinical development of ATI-1123 for non-small cell lung cancer in China, Taiwan and Korea, collaborating with Azaya on clinical trial design. Financial details of the arrangement were not disclosed. - See more at: http://www.chinabiotoday.com/articles/20130912_1#sthash.AcVTng61.dpuf
China based CANbridge life sciences has acquired exclusive development and commercialization rights to Azaya therapeutics lung cancer drug candidiate ATI-1123 for China south korea and Taiwan.
ATI-1123, is a Novel Human Serum Albumin-Stabilized Nanoparticle Docetaxel Liposomal Formulation.

Wednesday 11 September 2013

AstraZeneca and Merck & Co Inc enter into worldwide licensing agreement for Merck's oral small molecule inhibitor of WEE1 kinase (MK-1775)

AstraZeneca and Merck & Co Inc , known outside the United States and Canada as MSD,  today announced a worldwide licensing agreement for Merck's oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard of care therapies for the treatment of patients with certain types of ovarian cancer.

Tuesday 10 September 2013

Eddingpharm inlicenses China rights to Entinostat from Syndax Pharma

Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, a leading specialty pharmaceutical company in China, entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market and sell entinostat in China and certain other Asian countries/regions. Financial details are undisclosed but include milestone payments and royalties on future entinostat sales. Details of the agreement include:

Monday 9 September 2013

Otsuka to acquire Astex Pharmaceuticals for $886m

Otsuka Holdings will buy Astex for a total of around $886m at $8.50/share, a 27% premium to the 3 September closing price. The acquisition allows Otsuka to: 1) strengthen its drug-discovery research using Astex’ fragment-based drug discovery technology; 2) expand its development pipeline, including five anticancer compounds; and 3) receive royalty revenues for Dacogen to treat myelodysplastic syndrome (MDS) and acute myelocytic leukemia (AML).  Astex reported FY12/12 sales of $83m, an operating loss of $7m, and R&D spending of $60m